Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease

Anti-TNFα and anti-IL-23 antibodies are highly effective therapies for Crohn’s disease or ulcerative colitis in a proportion of patients. V56B2 is a novel bispecific domain antibody in which a llama-derived IL-23p19-specific domain antibody, humanised and engineered for intestinal protease resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Kevin J., Cubitt, Marion F., Carlton, Timothy M., Rodrigues-Duarte, Lurdes, Maggiore, Luana, Chai, Ray, Clare, Simon, Harcourt, Katherine, MacDonald, Thomas T., Ray, Keith P., Vossenkämper, Anna, West, Michael R., Crowe, J. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484351/
https://www.ncbi.nlm.nih.gov/pubmed/34593832
http://dx.doi.org/10.1038/s41598-021-97236-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484351/
https://www.ncbi.nlm.nih.gov/pubmed/34593832
http://dx.doi.org/10.1038/s41598-021-97236-0

Ejemplares similares